Abstract
The global SARS-CoV-2 pandemic prompted nations to implement mobility limitations to curb virus spread. In Chile, targeted interregional measures were employed to mitigate the social and economic costs. Here, we employ a novel real-time methodology to assess the impact of such mobility restrictions on epidemic control. Leveraging telecom-derived eXtended Detail Records (XDR) and official COVID-19 epidemiological data, we estimate interregional mobility and disease prevalence. Employing Bayesian adjustments, we compare different mobility restriction scenarios: business-as-usual (BAU), initial measures, and total lockdown. Mobility reductions significantly curtailed cases and risk across regions. Even modest mobility declines under total lockdowns considerably lowered imported cases. The high-risk Santiago Region, a national source of infections to other regions, demonstrated lowered risk due to mobility restrictions. Our approach facilitates rapid regional insights for informed policy responses.
Author summary The implementation of mobility restrictions is a coarse approach to limiting pathogen transmission during the early stages of an epidemic. Disentangling the effects of the reduced population mixing and the effects of new seeding events can be challenging to perform in real time, making any evaluation of the efficacy of such interventions a post hoc exercise. Here we present an approach that uses aggregated data from individual mobile phone locations within the national network of antennas to statistically correct for changes in human mobility and estimate the changes in COVID-19 transmission across regions in Chile during the first wave of the pandemic. We estimate a risk score that can be implemented nearly in real time to estimate the effects of mobility restrictions on viral transmission and highlight that important urban centres that seed other regions, like the Santiago Region, are at low risk of experiencing increased viral transmission due to new seeding events from other regions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
F and LB thank the funding and support of Telefonica R&D Chile and CISCO Chile. This research was supported by FONDECYT Grant No. 1130902 to Loreto Bravo and FONDECYT Grant No. 1221315 to Leo Ferres. BG acknowledges funding from the Oxford Martin School Pandemic Genomics programme and the European Union Horizon 2020 MOOD (#874850). LF also acknowledges financial support from the Lagrange Project of the Institute for Scientific Interchange Foundation (ISI Foundation), funded by Fondazione Cassa di Risparmio di Torino (Fondazione CRT).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study utilises anonymized, unidentifiable data collected from individual mobile phone devices and publicly available aggregated case count data in Chile. It does not use or access individual personal information, and has therefore been waived for an ethical approval. This decision was made by the Institutional Ethics Committee at Universidad del Desarrollo, Santiago de Chile, Chile, communicated to the authors on March 30, 2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data and code related to the analysis and figures in tis manuscript are publicly available at GitHub. Raw mobility data from individual mobile phones cannot be made publicly available to protect the individual privacy of users.
